MK 1454

Drug Profile

MK 1454

Alternative Names: MK-1454

Latest Information Update: 24 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators; Interferon stimulants; Interferon type I modulators; Interferon type I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in USA and Israel (Intratumoural)
  • 01 Jan 2017 Merck Sharp and Dohme plans a phase I trial for Solid tumours and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in USA (NCT03010176)
  • 08 Nov 2016 Preclinical trials in Solid tumours and Lymphoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top